Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Saturday, July 30, 2016

Remyelination Studies Abound, But How About a Workable Therapy?


Click here to receive MS news via e-mail


Remyelination at the moment is the buzzword to beat all buzzwords in the world of research into, and treatment for, the vicious disease that is multiple sclerosis.
Now, as you are reading this, you must have some knowledge of MS and are sure to know about the link between the loss of the myelin sheath and MS; that is why I am not going to repeat that here.
But the reason remyelination is making the headlines is that there is so much going on.
Earlier this year, researchers from the University of Cambridge showed that a membrane-bound signaling protein, EphrinB3, blocks the remyelination of damaged neurons in multiple sclerosis (MS). The study, “Antibody-mediated neutralization of myelin-associated EphrinB3 accelerates CNS re-myelination,” uncovered a new target to explore in the search for a new MS treatment.
Next, during a Phase 2 clinical trial testing the efficacy of a common antihistamine, clemastine fumarate, to treat optic nerve damage in people with multiple sclerosis, the drug was able to slightly reverse damage to their visual system.

MS Views and News
Providing educational information, resources and services for those affected by MS

No comments: